We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.34B
AUM Growth
+$140M
Cap. Flow
+$87.9M
Cap. Flow %
3.75%
Top 10 Hldgs %
23.56%
Holding
168
New
20
Increased
60
Reduced
15
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$65.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$38.6M
3
HCA icon
HCA Healthcare
HCA
+$36.9M
4
COR icon
Cencora
COR
+$28.3M
5
DVA icon
DaVita
DVA
+$24M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$67.4M
2
CI icon
Cigna
CI
+$65.2M
3
MRK icon
Merck
MRK
+$47.9M
4
JNJ icon
Johnson & Johnson
JNJ
+$27.9M
5
WTW icon
Willis Towers Watson
WTW
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.66%
2 Financials 1.72%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
51
Align Technology
ALGN
$12.3B
$16.4M 0.7%
65,500
-1,250
-2% -$321K
XENT
52
DELISTED
Intersect ENT, Inc
XENT
$16.1M 0.69%
410,000
+65,000
+19% +$2.37M
ZBH icon
53
Zimmer Biomet
ZBH
$18.4B
$16.1M 0.69%
151,925
+29,355
+24% +$3.41M
NUVA
54
DELISTED
NuVasive, Inc.
NUVA
$15.9M 0.68%
+305,000
New +$15.5M
TBPH icon
55
Theravance Biopharma
TBPH
$877M
$15.8M 0.68%
652,600
– –
INCY icon
56
Incyte
INCY
$24.4B
$15.2M 0.65%
182,500
– –
FOLD
57
DELISTED
Amicus Therapeutics
FOLD
$15M 0.64%
1,000,000
+90,000
+10% +$1.37M
HOLX
58
DELISTED
Hologic
HOLX
$14.9M 0.64%
400,000
+65,000
+19% +$2.63M
EXAS
59
DELISTED
Exact Sciences
EXAS
$14.9M 0.64%
370,500
-64,400
-15% -$3.14M
ARNA
60
DELISTED
Arena Pharmaceuticals Inc
ARNA
$14.8M 0.63%
375,000
+160,000
+74% +$6.22M
BIIB icon
61
Biogen
BIIB
$30.7B
$14.5M 0.62%
53,000
– –
BPMC
62
DELISTED
Blueprint Medicines
BPMC
$14.5M 0.62%
157,753
+11,253
+8% +$970K
KYNB
63
Kyntra Bio
KYNB
$29.4M
$14.3M 0.61%
12,380
-620
-5% -$816K
ANAB icon
64
AnaptysBio
ANAB
$1.68B
$14.1M 0.6%
135,000
-7,400
-5% -$834K
INGN icon
65
Inogen
INGN
$164M
$13.6M 0.58%
110,500
+30,500
+38% +$3.72M
HRTX icon
66
Heron Therapeutics
HRTX
$92.9M
$13.1M 0.56%
476,000
+226,000
+90% +$5.13M
YARW
67
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$12.4M 0.53%
+92
New +$11.2M
CLVS
68
DELISTED
Clovis Oncology, Inc.
CLVS
$12.2M 0.52%
231,500
– –
IDXX icon
69
Idexx Laboratories
IDXX
$46.2B
$12.1M 0.51%
+63,000
New +$11.6M
AMRN
70
Amarin Corp
AMRN
$303M
$12M 0.51%
200,000
+2,500
+1% +$186K
PRTA icon
71
Prothena Corp
PRTA
$450M
$11.7M 0.5%
318,500
+8,500
+3% +$309K
ARDX icon
72
Ardelyx
ARDX
$997M
$11.5M 0.49%
2,275,557
– –
OBSV
73
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.3M 0.48%
840,000
– –
QTTB icon
74
Q32 Bio
QTTB
$464M
$10.8M 0.46%
+31,944
New +$10.7M
GTHX
75
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$10.6M 0.45%
287,000
+72,500
+34% +$1.93M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rock Springs Capital Management held 168 positions worth $2.34B, up 6.4% from $2.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management deployed $87.9M of net new capital in Q1 2018, opening 20 new positions and adding to 60 existing holdings. Its largest new stake was AbbVie: 600,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was PRA Health Sciences, Inc., an estimated $7.33M trimmed.

  • Rock Springs Capital Management's largest Q1 2018 buy was AbbVie: 600,000 shares worth $56.8M.
  • Rock Springs Capital Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $38.6M increase.
  • Rock Springs Capital Management's biggest Q1 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $7.33M.
  • Rock Springs Capital Management fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $67.4M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $2.34B portfolio in Q1 2018.
  • Rock Springs Capital Management opened 20 new positions and closed 19 in Q1 2018.
  • Rock Springs Capital Management's portfolio value rose 6.4% quarter-over-quarter to $2.34B.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.